Scientific Oracle
R&D decisions
Evidence maps, portfolio choices, due diligence, milestone logic, and stop conditions before expensive commitments.
Start here
An R&D Go/No-Go Framework With Real Stop Conditions
Supporting guides
- An R&D Go/No-Go Framework With Real Stop Conditions
Treat An R&D Go/No-Go Framework With Real Stop Conditions as a ranking problem rather than a request for certainty. Define the decision about whether a program should proceed, pause, reframe, or stop at the next gate, assemble milestone criteria, method fidelity, uncertainty, differentiation, downstream cost, and alternative routes, and test whether the preferred route still leads after you predeclare the result range that makes no-go mandatory. The recommendation remains bounded by the evidence and accountable specialist validation.
- Scientific Due Diligence: A Falsifier-First Guide
The practical question behind Scientific Due Diligence is which scientific claims materially affect a funding, partnership, or development decision. Rank credible alternatives with claim provenance, methods, data access, reproducibility, alternative explanations, and missing validation, expose the strongest counterargument, and challenge the leader by trying to construct the strongest evidence-based case against the thesis and test whether the decision changes. A useful answer changes the next allocation decision without pretending computation is final proof.
- Biotech Scientific Due Diligence Before Funding the Next Milestone
Biotech Scientific Due Diligence Before Funding the Next Milestone becomes decision-useful when the team states which biological or translational claim is load-bearing for the investment thesis, not when it collects another undirected summary. Use target biology, human relevance, assay validity, model limitations, safety signals, and competitive context to compare mechanisms and run this early falsifier: remove the weakest translational bridge and see whether the milestone still creates value. Continue only if the ranking survives.
- Deep-Tech Technical Due Diligence: Test the Physics Behind the Story
Before funding deeper validation, Deep-Tech Technical Due Diligence should resolve which technical assumptions determine feasibility and scale-up risk. The minimum credible analysis compares distinct routes using governing equations, material constraints, energy and mass balances, prototypes, tolerances, and failure modes and attempts to run an order-of-magnitude constraint check before detailed forecasting. The result should name the leading direction, the counterevidence, and the condition that would stop it.
- How to Prioritize R&D Projects Without Hiding Judgment in a Score
How to Prioritize R&D Projects Without Hiding Judgment in a Score can shorten the search only by eliminating weak directions early. Start with which projects deserve scarce people, time, and validation budget; compare mechanisms against strategic fit, evidence maturity, information gain, feasibility, reversibility, differentiation, and option value; and try to break the ranking with this challenge: vary weights and remove one criterion at a time to test ranking stability. A negative result is valuable when it prevents the wrong validation cycle.
- R&D Portfolio Prioritization Under Scientific Uncertainty
For R&D Portfolio Prioritization Under Scientific Uncertainty, speed comes from a precise decision and a fast falsifier. State how to balance several uncertain programs rather than select one in isolation, evaluate competing routes with correlated risks, shared platforms, resource bottlenecks, stage, upside, learning value, and kill criteria, and attempt to simulate adverse outcomes across correlated programs and test portfolio resilience. The output is an inspectable next-direction recommendation, not a substitute for laboratory, clinical, engineering, or regulatory validation.
- Research Stop Conditions: Decide Before the Results Arrive
For Research Stop Conditions, the bounded choice is what evidence should terminate or materially redesign a research route. Compare at least three live alternatives using failure thresholds, replication requirements, resource caps, safety boundaries, and alternative value, then run the cheapest ranking-reversal test: apply the rule retrospectively to prior decisions and check whether it would have been honored. The defensible output is pursue, reframe, or stop—not final validation.
- Kill Criteria for Innovation Projects Without Punishing Honest Failure
Use Kill Criteria for Innovation Projects Without Punishing Honest Failure to decide how to close weak routes while preserving learning and team candor before the next expensive commitment. Build the comparison around method completion, hypothesis failure, market or technical constraints, salvageable assets, and next-best options and ask what would overturn the preferred route; the earliest useful challenge is: separate failure of the hypothesis from failure to execute the agreed method. Stop at a provisional decision and preserve the remaining validation boundary.
- Design R&D Milestones Around Evidence, Not Activity
The practical question behind Design R&D Milestones Around Evidence, Not Activity is which milestone demonstrates decision-relevant learning rather than task completion. Rank credible alternatives with claim tested, acceptance criterion, evidence artifact, uncertainty, adverse-outcome handling, and owner, expose the strongest counterargument, and challenge the leader by trying to ask whether the milestone can pass while the core technical risk remains untouched. A useful answer changes the next allocation decision without pretending computation is final proof.
- Build an Evidence Map for an R&D Decision
Build an Evidence Map for an R&D Decision becomes decision-useful when the team states how to organize heterogeneous evidence before ranking directions, not when it collects another undirected summary. Use claims, sources, support, contradiction, provenance, independence, uncertainty, and missing tests to compare mechanisms and run this early falsifier: have an independent reviewer reconstruct the recommendation from the ledger alone. Continue only if the ranking survives.
- R&D Decision Matrices: Useful Tool or False Precision?
Before funding deeper validation, R&D Decision Matrices should resolve whether a weighted comparison clarifies or obscures the choice. The minimum credible analysis compares distinct routes using criterion definitions, scales, weights, uncertainty, dependencies, veto conditions, and sensitivity and attempts to perturb weights within plausible ranges and report ranking reversals. The result should name the leading direction, the counterevidence, and the condition that would stop it.
- Choose the Next Experiment by Expected Information Gain
Treat Choose the Next Experiment by Expected Information Gain as a ranking problem rather than a request for certainty. Define the decision about which experiment best separates live alternatives before a larger commitment, assemble candidate predictions, outcome probabilities, measurement noise, cost, time, and decision consequences, and test whether the preferred route still leads after you compare the expected ranking change under every plausible result. The recommendation remains bounded by the evidence and accountable specialist validation.
- Sunk Cost in R&D: How to Reopen a Protected Decision
Sunk Cost in R&D can shorten the search only by eliminating weak directions early. Start with whether continued investment reflects new evidence or accumulated commitment; compare mechanisms against forward-looking value, unresolved risks, alternative uses, switching cost, team incentives, and prior forecasts; and try to break the ranking with this challenge: restate the decision as if the program were offered today with no ownership history. A negative result is valuable when it prevents the wrong validation cycle.
- When an R&D Program Produces Data but No Decision
For When an R&D Program Produces Data but No Decision, speed comes from a precise decision and a fast falsifier. State how to diagnose a program that keeps learning without moving, evaluate competing routes with decision ownership, hypotheses, discriminating contrasts, milestone criteria, data quality, and unresolved contradictions, and attempt to name one result that would force a route change; if none exists, reframe the program. The output is an inspectable next-direction recommendation, not a substitute for laboratory, clinical, engineering, or regulatory validation.
- A Scientific Project Pre-Mortem Before the Next Budget Release
For A Scientific Project Pre-Mortem Before the Next Budget Release, the bounded choice is which plausible failure modes should alter the plan before work begins. Compare at least three live alternatives using technical assumptions, measurement, data, dependencies, scale-up, safety, and organizational incentives, then run the cheapest ranking-reversal test: ask independent reviewers to explain a future failure using evidence available now. The defensible output is pursue, reframe, or stop—not final validation.
- How to Red-Team a Scientific Claim
Use How to Red-Team a Scientific Claim to decide whether a claim survives adversarial source, method, and mechanism review before the next expensive commitment. Build the comparison around definitions, data provenance, exclusions, statistics, alternative explanations, generalization, and incentives and ask what would overturn the preferred route; the earliest useful challenge is: reproduce the decisive analysis from raw or independently obtained data. Stop at a provisional decision and preserve the remaining validation boundary.
- Evidence Before Scale-Up: What Must Survive First?
The practical question behind Evidence Before Scale-Up is which technical and scientific claims should be challenged before scale-up. Rank credible alternatives with mass and energy balance, variability, boundary conditions, degradation, controls, and process sensitivity, expose the strongest counterargument, and challenge the leader by trying to stress the model at the nearest plausible operating boundary. A useful answer changes the next allocation decision without pretending computation is final proof.
- Scenario Analysis for Scientific R&D Decisions
Scenario Analysis for Scientific R&D Decisions becomes decision-useful when the team states how the decision changes across plausible technical outcomes, not when it collects another undirected summary. Use state variables, dependencies, uncertainty ranges, decision thresholds, and irreversible commitments to compare mechanisms and run this early falsifier: include a hostile but plausible scenario and report whether the strategy remains viable. Continue only if the ranking survives.
- Technology Readiness Is an Evidence Claim, Not a Marketing Number
Before funding deeper validation, Technology Readiness Is an Evidence Claim, Not a Marketing Number should resolve what evidence supports the stated maturity of a technology. The minimum credible analysis compares distinct routes using operating environment, integration, repeatability, scale, verification artifacts, and unresolved risks and attempts to ask whether the evidence was produced in the environment implied by the readiness claim. The result should name the leading direction, the counterevidence, and the condition that would stop it.
- Test the Technical Thesis Before the Investment Committee
Treat Test the Technical Thesis Before the Investment Committee as a ranking problem rather than a request for certainty. Define the decision about which technical fact could most change the capital-allocation decision, assemble mechanism, performance, reproducibility, scale constraints, competitive benchmark, and validation path, and test whether the preferred route still leads after you identify the fastest independent result that would make the thesis unattractive. The recommendation remains bounded by the evidence and accountable specialist validation.
- Option Value in R&D: Fund Learning Without Pretending It Is Validation
Option Value in R&D can shorten the search only by eliminating weak directions early. Start with whether a small milestone creates a valuable option on deeper work; compare mechanisms against learning objective, cost cap, branching decisions, salvage value, evidence threshold, and follow-on rights; and try to break the ranking with this challenge: test whether the milestone still has value under a negative result. A negative result is valuable when it prevents the wrong validation cycle.
- Check Reproducibility Before Funding the Next Scientific Step
For Check Reproducibility Before Funding the Next Scientific Step, speed comes from a precise decision and a fast falsifier. State which result must be reproducible for the program thesis to remain credible, evaluate competing routes with raw data, code, protocol, environment, exclusions, random seeds, and independent execution, and attempt to re-run the decisive result from a clean environment or independent dataset. The output is an inspectable next-direction recommendation, not a substitute for laboratory, clinical, engineering, or regulatory validation.
- An Evidence-Quality Framework for Technical Claims
For An Evidence-Quality Framework for Technical Claims, the bounded choice is how much confidence a technical claim deserves at the current stage. Compare at least three live alternatives using directness, independence, method quality, uncertainty, replication, relevance, and conflicts, then run the cheapest ranking-reversal test: cap the claim at the weakest load-bearing evidence link. The defensible output is pursue, reframe, or stop—not final validation.
- Research Prioritization for a Small Team With Too Many Questions
Use Research Prioritization for a Small Team With Too Many Questions to decide which question creates the most decision-relevant learning within capacity before the next expensive commitment. Build the comparison around bottlenecks, dependencies, information gain, effort, reuse, risk, and deadline and ask what would overturn the preferred route; the earliest useful challenge is: choose the question whose answer changes the largest number of downstream choices. Stop at a provisional decision and preserve the remaining validation boundary.
- When to Commission Computational Research—and When Not To
The practical question behind When to Commission Computational Research—and When Not To is whether existing evidence and computation can reduce the decision uncertainty. Rank credible alternatives with data availability, modelability, source quality, decision stakes, turnaround, and validation ownership, expose the strongest counterargument, and challenge the leader by trying to attempt a bounded feasibility scan before defining a larger commission. A useful answer changes the next allocation decision without pretending computation is final proof.